Polyoxometalate inhibition of SOX2-mediated tamoxifen resistance in breast cancer-Reference-Cited by-同舟云学术

Polyoxometalate inhibition of SOX2-mediated tamoxifen resistance in breast cancer

Published:2024-09-02 Issue:1 Volume:22 Page:
ISSN:1478-811X
Container-title:Cell Communication and Signaling
language:en
Short-container-title:Cell Commun Signal

Author:

Aurrekoetxea-Rodriguez Iskander,Lee So Young,Rábano Miriam,Gris-Cárdenas Isabel,Gamboa-Aldecoa Virginia,Gorroño Irantzu,Ramella-Gal Isabella,Parry Connor,Kypta Robert M.,Artetxe Beñat,Gutierrez-Zorrilla Juan M.,Vivanco Maria dM.

Funder

Ministerio de Ciencia e Innovación

Eusko Jaurlaritza

Ministerio de Ciencia, Innovación y Universidades

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1186/s12964-024-01800-w.pdf

Reference59 articles.

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.

2. Font-Diaz J, Jimenez-Panizo A, Caelles C, Vivanco MD, Perez P, Aranda A, Estebanez-Perpina E, Castrillo A, Ricote M, Valledor AF. Nuclear receptors: lipid and hormone sensors with essential roles in the control of cancer development. Semin Cancer Biol. 2021;73:58–75.

3. Pan H, Gray R, Braybrooke J, Davies C, Taylor C, McGale P, Peto R, Pritchard KI, Bergh J, Dowsett M, et al. 20-Year risks of breast-Cancer recurrence after stopping endocrine therapy at 5 years. N Engl J Med. 2017;377:1836–46.

4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869–74.

5. Martelotto LG, Ng CK, Piscuoglio S, Weigelt B, Reis-Filho JS. Breast cancer intra-tumor heterogeneity. Breast Cancer Res. 2014;16:210.